{
    "clinical_study": {
        "@rank": "14774", 
        "arm_group": [
            {
                "arm_group_label": "Panel A: Mild/Moderate Hypertension", 
                "arm_group_type": "Experimental", 
                "description": "MK-8150 or matching placebo once daily, capsules, oral, for 10 days"
            }, 
            {
                "arm_group_label": "Panel B: Mild/Moderate Hypertension", 
                "arm_group_type": "Experimental", 
                "description": "MK-8150 or matching placebo once daily, capsules, oral, for 10 days"
            }, 
            {
                "arm_group_label": "Panel C: Mild/Moderate Hypertension", 
                "arm_group_type": "Experimental", 
                "description": "MK-8150 or matching placebo once daily, capsules, oral, for 10 days"
            }, 
            {
                "arm_group_label": "Panel D: Mild/Moderate Hypertension", 
                "arm_group_type": "Experimental", 
                "description": "MK-8150 or matching placebo once daily, capsules, oral, for 10 days"
            }, 
            {
                "arm_group_label": "Panel E-Elderly", 
                "arm_group_type": "Experimental", 
                "description": "Single dose of MK-8150 or placebo on Study Day 1 followed by a wash-out of at least 5 days, then MK-8150 or placebo once daily at a lower dose for 10 days"
            }, 
            {
                "arm_group_label": "Panel F - Elderly", 
                "arm_group_type": "Experimental", 
                "description": "Single dose of MK-8150 or placebo on Study Day 1 followed by a wash-out of at least 5 days, then MK-8150 or placebo once daily at a lower dose for 10 days"
            }, 
            {
                "arm_group_label": "Panel G - Healthy - Dose Titration", 
                "arm_group_type": "Experimental", 
                "description": "MK-8150 or matching placebo will be administered once daily for 28 days. Dose may be adjusted on Day 8, Day 15, and Day 22."
            }, 
            {
                "arm_group_label": "Panel H - Crossover", 
                "arm_group_type": "Experimental", 
                "description": "MK-8150 or matching placebo for 10 consecutive days in 2-period crossover with minimum 3 weeks washout period between the 2 treatment periods"
            }, 
            {
                "arm_group_label": "Panel I - Dose Titration", 
                "arm_group_type": "Experimental", 
                "description": "MK-8150 or matching placebo will be administered once daily for 28 days. Dose may be adjusted on Day 8, Day 15, and Day 22."
            }, 
            {
                "arm_group_label": "Panel J - Dose Titration", 
                "arm_group_type": "Experimental", 
                "description": "MK-8150 or matching placebo will be administered once daily for 28 days. Dose may be adjusted on Day 8, Day 15, and Day 22."
            }
        ], 
        "brief_summary": {
            "textblock": "This study will evaluate the safety and tolerability of MK-8150 after multiple, rising oral\n      dose administration in healthy male participants, male participants with mild to moderate\n      hypertension and elderly participants with mild to moderate hypertension."
        }, 
        "brief_title": "A Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MK-8150 (MK-8150-002)", 
        "completion_date": {
            "#text": "May 2013", 
            "@type": "Actual"
        }, 
        "condition": [
            "Hypertension", 
            "Isolated Systolic Hypertension"
        ], 
        "condition_browse": {
            "mesh_term": "Hypertension"
        }, 
        "detailed_description": {
            "textblock": "Ten panels (Panels A-J), consisting of 104 participants in total, will be randomized to\n      receive either MK-8150 or matching placebo.\n\n      Males (18 to 55 years of age, inclusive) with mild to moderate hypertension will be\n      randomized in Panels A-D and will receive either MK-8150 or placebo as once daily treatment\n      for 10 consecutive days.\n\n      Elderly males and females (65 to 80 years of age, inclusive) with mild to moderate\n      hypertension will be included in Panels E and F and will receive a single dose of either\n      MK-8150 or placebo on Study Day 1 followed by at least 5 days of wash-out before proceeding\n      to once daily treatment of the same randomized treatment at a lower dose for 10 consecutive\n      days.\n\n      Participants 18 to 65 years of age with resistant hypertension  will be enrolled in Panels H\n      and will receive in randomized sequences of MK-8150/placebo or placebo/MK-8150 in 2\n      treatment periods. There will be a minimum 3 weeks washout period between the 2 treatment\n      periods in Panel H.\n\n      Healthy males (18 to 55 years of age, inclusive) will be enrolled in Panel G and will\n      receive MK-8150 or matching placebo once daily for 28 days. Participants randomized to\n      MK-8150 in Panel G who meet all of the dose-escalation criteria and have not met any of the\n      hemodynamic stopping criteria will be eligible for dose increases on Day 8, Day 15, and Day\n      22. If dose escalation criteria are not met (or if the Investigator or Sponsor elects not to\n      increase the dose), then the participant will continue on the current dose and will be\n      eligible for a dose increase at the next dose-escalation decision day if all dose-escalation\n      criteria are met at that time.\n\n      Male participants (18 to 65 years of age, inclusive) with mild to moderate hypertension will\n      be randomized in Panels I and J. In each panel, 18 participants will receive either MK-8150\n      or matching placebo as once daily treatment for up to 28 consecutive days. Participants who\n      are randomized to placebo will receive placebo throughout the study. On Days 8, 15 and 22 in\n      both Panels I and J, participants will be eligible for dose-escalation, down-dosing, or\n      continuing their current dose depending on their hemodynamic status. Participants in Panels\n      I and J who meet down-dosing criteria at any time during the study will have their doses\n      reduced to the previous well-tolerated\n\n      dose level until the next dose-escalation decision day, or through the end of the study,\n      whichever is first."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Hypertensive male participant between 18 to 55 years of age for Panels A to D;\n             hypertensive male or female of non-childbearing potential between 65 to 80 years of\n             age for Panels E and F; healthy males between 18 to 55 years of age for Panel G;\n             hypertensive male or non-childbearing potential female between 18 to 65 years of age\n             (inclusive) for Panel H; hypertensive male between 18 to 65 years of age for Panels I\n             and J\n\n          -  Body Mass Index (BMI) \u2264 33 kg/m^2\n\n          -  In good age appropriate health\n\n          -  No history of clinically significant cardiac disease\n\n          -  Nonsmoker and/or has not used nicotine or nicotine-containing products for at least 6\n             months\n\n        Exclusion Criteria:\n\n          -  Mentally or legally incapacitated, has significant emotional problems or has a\n             history of a clinically significant psychiatric disorder over the last 5 years\n\n          -  History of stroke, chronic seizures, or a relevant major neurological disorder\n\n          -  History of neoplastic disease (cancer)\n\n          -  Unable to refrain from or anticipates the use of any medication, including any\n             non-steroidal anti-inflammatory drug  (NSAID) and aspirin-containing products,\n             prescription and non-prescription drugs or herbal remedies for 2 weeks prior to study\n             start up to end of study\n\n          -  Anticipates using erectile dysfunction medications during the study\n\n          -  Uses or anticipates using organic nitrates during the course of the study (e.g.\n             nitroglycerin, isosorbide mononitrate, isosorbide dinitrate, pentaerythritol)\n\n          -  Consumes excessive amounts of alcohol, defined as greater than 3 glasses of alcoholic\n             beverages (1 glass is approximately equivalent to: beer [284 mL/10 ounces], wine [125\n             mL/4 ounces], or distilled spirits [25 mL/1 ounce]) per day\n\n          -  Has had major surgery, donated or lost 1 unit of blood or participated in another\n             investigational study within 4 weeks\n\n          -  History of significant multiple and/or severe allergies (including latex allergy)\n\n          -  Current regular user (including ) of any illicit drugs or has a history of drug\n             (including alcohol) abuse within approximately 1 year"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "80 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "103", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "July 12, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01656408", 
            "org_study_id": "8150-002", 
            "secondary_id": "2012-002596-34"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Panel A: Mild/Moderate Hypertension", 
                    "Panel B: Mild/Moderate Hypertension", 
                    "Panel C: Mild/Moderate Hypertension", 
                    "Panel D: Mild/Moderate Hypertension", 
                    "Panel E-Elderly", 
                    "Panel F - Elderly", 
                    "Panel G - Healthy - Dose Titration", 
                    "Panel H - Crossover", 
                    "Panel I - Dose Titration", 
                    "Panel J - Dose Titration"
                ], 
                "intervention_name": "MK-8150", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Panel A: Mild/Moderate Hypertension", 
                    "Panel B: Mild/Moderate Hypertension", 
                    "Panel C: Mild/Moderate Hypertension", 
                    "Panel D: Mild/Moderate Hypertension", 
                    "Panel E-Elderly", 
                    "Panel F - Elderly", 
                    "Panel G - Healthy - Dose Titration", 
                    "Panel H - Crossover", 
                    "Panel I - Dose Titration", 
                    "Panel J - Dose Titration"
                ], 
                "intervention_name": "Placebo for MK-8150", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "September 6, 2013", 
        "number_of_arms": "10", 
        "official_title": "A Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MK-8150", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Belgium: Federal Agency for Medicinal Products and Health Products", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "May 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "measure": "Number of Participants who Report an Adverse Event", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 28 days"
            }, 
            {
                "measure": "Number of Participants Discontinued per Panel due to Meeting Hemodynamic Stopping Rules", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 28 days"
            }, 
            {
                "measure": "24-hour Time-weighted Average (TWA0-24hr) Change from Baseline in Central Systolic Blood Pressure (cSBP)", 
                "safety_issue": "No", 
                "time_frame": "Panels A-F and H: Predose, Day 1 (up to 24 hours postdose) and Day 10 (up to 24 hours postdose) and Panels G and I-J: Predose, Day 1 (up to 24 hours postdose) and  Days  8, 15, 22, and 28 (up to 24 hours postdose)"
            }, 
            {
                "measure": "24-hour Weighted Average Change from Baseline in Heart Rate (HR TWA0-24hrs)", 
                "safety_issue": "No", 
                "time_frame": "Panels A-F and H: Predose, Day 1 (up to 24 hours postdose) and Day 10 (up to 24 hours postdose) and Panels G and I-J: Predose, Day 1 (up to 24 hours postdose) and Days 8, 15, 22, and 28 (up to 24 hours postdose)"
            }, 
            {
                "measure": "Area Under the Concentration Time-curve from Hour 0 to \u03c4 (where \u03c4 indicates the interval between doses [AUC(0-\u03c4)]) of MK-8150", 
                "safety_issue": "No", 
                "time_frame": "Panels A-D and H- Day 1 and Day 10; Panels E-F- Day 1, Day 6 and Day 15; Panels G, I-J - Days 1, 8, 15, 22, and 28"
            }, 
            {
                "measure": "Maximum Plasma Concentration (Cmax) of MK-8150", 
                "safety_issue": "No", 
                "time_frame": "Panels A-D and H- Day 1 and Day 10; Panels E-F- Day 1, Day 6 and Day 15; Panels G, I-J - Days 1, 8, 15, 22, and 28"
            }, 
            {
                "measure": "Time to Cmax (Tmax) for MK-8150", 
                "safety_issue": "No", 
                "time_frame": "Panels A-D and H- Day 1 and Day 10; Panels E-F- Day 1, Day 6 and Day 15; Panels G, I-J - Days 1, 8, 15, 22, and 28"
            }, 
            {
                "measure": "Apparent Terminal Half-life (t1/2) for MK-8150", 
                "safety_issue": "No", 
                "time_frame": "Panels A-D and H- Day 1 and Day 10; Panels E-F- Day 1, Day 6 and Day 15; Panels G, I-J - Days 1, 8, 15, 22, and 28"
            }
        ], 
        "removed_countries": {
            "country": "Belgium"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01656408"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Merck Sharp & Dohme Corp.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Merck Sharp & Dohme Corp.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "August 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "September 2013"
    }
}